Special Issue "Carbonic Anhydrases and Metabolism"
A special issue of Metabolites (ISSN 2218-1989).
Deadline for manuscript submissions: closed (21 December 2018) | Viewed by 68100
A printed edition of this Special Issue is available here.
Interests: drug design; metalloenzymes; carbonic anhydrases; anticancer agents; antiinfectives; sulfonamides; coumarins
Special Issues, Collections and Topics in MDPI journals
Special Issue in Metabolites: Cancer Metabolomics 2016
Special Issue in Pathogens: Pathogen Legionella pneumophila
Special Issue in International Journal of Molecular Sciences: Enzyme-Inhibitor Interaction as Examples of Molecular Recognition
Special Issue in Molecules: Sulfonamides
Special Issue in Marine Drugs: Carbonic Anhydrase in Marine Organism
Special Issue in Molecules: Metalloenzyme Inhibitors and Activators
Special Issue in International Journal of Molecular Sciences: Protease and Carbonic Anhydrase Inhibitors and Their Roles in Pathological Processes
Special Issue in Metabolites: Carbonic Anhydrases and Metabolism Volume 2
Special Issue in International Journal of Molecular Sciences: 23rd Anniversary of IJMS: Advances in Biochemistry
Special Issue in International Journal of Molecular Sciences: Protease and Carbonic Anhydrase Inhibitors, II
Special Issue in International Journal of Molecular Sciences: Biochemistry, Molecular Biology and Druggability of Proteins
Special Issue in Metabolites: Metabolism in the Tumor Microenvironment
Special Issue in International Journal of Molecular Sciences: Carbonic Anhydrase and Carbonic Anhydrase Inhibitors
Special Issue in International Journal of Molecular Sciences: Tackling New and Reemerging Infectious Diseases through the Development of Novel Anti-infectives
Special Issue in Molecules: Feature Reviews in Bioorganic Chemistry
Topical Collection in International Journal of Molecular Sciences: Feature Paper Collection in Biochemistry
Special Issue in International Journal of Molecular Sciences: Carbonic Anhydrase and Carbonic Anhydrase Inhibitors 2.0
Carbonic anhydrases (CAs, EC 220.127.116.11) are metalloenzymes present in all life kingdoms, as they equilibrate the reaction between three simple but essential chemical species: CO2, bicarbonate, and protons. Discovered more than 80 year ago, in 1933, these enzymes were extensively investigated due to the biomedical application of their inhibitors, but also because they are an extraordinary example of convergent evolution, with seven genetically-distinct CA families that evolved independently in Bacteria, Archaea, and Eukarya. CAs are also among the most efficient enzymes known in nature, due to the fact that the uncatalyzed CO2 hydration is a very slow process, and the physiologic demands for its conversion to ionic, soluble species is very high. Inhibition of the CAs has pharmacologic applications in many fields, such as antiglaucoma, anticonvulsant, antiobesity, and anticancer agents/diagnostic tools, but is also emerging for designing anti-infectives, i.e., antifungal, antibacterial and antiprotozoan agents with a novel mechanism of action. Mitochondrial CAs are implicated in de novo lipogenesis allowing the ability to consider selective inhibitors of such enzymes as useful for the development of new antiobesity drugs. As the tumor metabolism is diverse form that of normal cells, ultimately, relevant contributions on the role of the tumor-associated isoforms CA IX and XII in these phenomena have been published, and the two isoforms have been validated as novel antitumor/antimetastatic drug targets, with antibodies and small molecule inhibitors in various stages of clinical development. CAs also play a crucial role in other metabolic processes connected with urea biosynthesis, gluconeogenesis, etc., since many carboxylation reactions catalyzed by acetyl-coenzyme A carboxylase or pyruvate carboxylase use bicarbonate not CO2 as a substrate. In organisms other than mammals, e.g., plants, algae, and cyanobacteria, CAs are involved in photosynthesis, whereas, in many parasites (fungi, protozoa), they are involved in the de novo synthesis of important metabolites (lipids, nucleic acids, etc.). The metabolic effects related to interference with CA activity were, however, scarcely investigated. The present Special Issue of Metabolites has the goal of filling this gap, by presenting the latest developments in the field of CAs and their role in metabolism.
Prof. Dr. Claudiu T. Supuran
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- carbonic anhydrase
- mitochondrial isoforms
- tumor-associated isoforms
- antiobesity drug
- anticancer drug